Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8933 results

  1. Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]

    Awaiting development Reference number: GID-TA11966 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  3. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development Reference number: GID-TA10981 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  6. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  7. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Vulnerable populations: strategies for tackling inequalities

    Awaiting development Reference number: GID-QS10124 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development